SEC Tracker
Get the app
TRVI · XBRL financial data

Trevi Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TRVI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development6,3236,518*8,80410,02111,2249,328*7,8119,38910,0856,193*9,94115,152
General and administrative2,7222,415*3,1023,2682,8632,915*3,6594,3333,8314,027*4,9715,357
Total operating expenses9,0458,933*11,90613,28914,08712,243*11,47013,72213,91610,220*14,91220,509
Operating income (loss)(9,045)(8,933)*(11,906)(13,289)(14,087)(12,243)*(11,470)(13,722)(13,916)(10,220)*(14,912)(20,509)
Interest income1,1831,137*998935826843*1,1251,4072,1011,903*1,6962,696
Interest expense34*1111*—000*——
Other income (expense)154(3)*(1)(5)(11)2*(6)(7)(2)(15)*4(3)
Income tax expense (benefit)(13)18*(8)(8)(31)16*(11)(21)(15)(16)*(20)(19)
Net income (loss)(7,698)(7,821)*(10,902)(12,352)(13,242)(11,415)*(10,340)(12,301)(11,802)(8,316)*(13,192)(17,797)
Earnings per share, basic USD per share(0.08)(0.08)*(0.11)(0.12)(0.13)(0.11)*(0.09)(0.09)(0.08)(0.06)*(0.09)(0.11)
Earnings per share, diluted USD per share(0.08)(0.08)*(0.11)(0.12)(0.13)(0.11)*(0.09)(0.09)(0.08)(0.06)*(0.09)(0.11)
Weighted average shares, basic thousands of shares99,32699,486*99,517101,042101,282106,010*117,611130,350145,105145,502*145,593156,602
Weighted average shares, diluted thousands of shares99,32699,486*99,517101,042101,282106,010*117,611130,350145,105145,502*145,593156,602

Balance sheet

CSV

Fiscal quarters (TRVI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents25,96532,39713,81112,96316,05234,09719,374117,05856,86918,91419,41254,302
Marketable securities62,90350,57459,00956,53249,44173,52583,88386,827138,058169,346152,371264,568
Total current assets93,95387,54776,76672,12967,336109,428105,621207,228198,299191,656176,121325,705
Property and equipment, net238216204198174157277239213178265336
Right-of-use asset1,1901,1371,0841,029973915865804741677610542
Total assets95,89689,40378,55973,81068,908110,900107,004208,339199,356193,439179,606330,518
Accounts payable1,2561,8092,1121,5111,6143,4141,4212,9742,7093,9112,2153,098
Accrued liabilities3,6253,7092,8424,9327,2126,8105,1695,9816,0365,5314,5825,309
Total current liabilities5,1735,8245,2766,7529,12310,5096,8669,2419,0419,7497,1158,736
Lease liability, non-current1,0511,001949884816747681605527446364276
Total liabilities6,2866,8566,2257,6369,93911,2567,5479,8469,56810,1957,4799,012
Accumulated deficit(231,313)(239,134)(250,036)(262,388)(275,630)(287,045)(297,385)(309,686)(321,488)(329,804)(342,996)(360,793)
Total stockholders' equity89,61082,54772,33466,17458,96999,64499,457198,493189,788183,244172,127321,506
Total liabilities and equity95,89689,40378,55973,81068,908110,900107,004208,339199,356193,439179,606330,518
Common shares outstanding (cover page) thousands of shares63,85868,96070,43572,59276,86696,682101,745121,777128,230128,397141,980142,476

Cash flows

CSV

Fiscal quarters (TRVI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(7,698)(7,821)*(10,902)(12,352)(13,242)(11,415)*(10,340)(12,301)(11,802)(8,316)*(13,192)(17,797)
Stock-based compensation530534*7231,127822917*1,2081,3841,2431,350*2,1913,272
Depreciation and amortization35*35*3538*36*38*3738*38*31*3434*
Net cash from operating activities(7,279)*(6,359)*(10,467)(8,683)*(9,556)*(9,550)*(13,477)(10,101)*(10,880)*(7,631)*(16,689)(17,429)*
Purchases of property and equipment18*22*——0*7*——12*0*102124*
Net cash from investing activities17,982*12,845*(8,091)2,768*7,667*(23,872)*(9,951)(2,610)*(50,938)*(30,608)*16,965(112,038)*
Repayments of long-term debt0*———————————
Net cash from financing activities1,510*(54)*(28)5,067*4,978*51,467*8,705110,395*1,629*284*222164,357*
Net change in cash12,213*6,432*(18,586)(848)*3,089*18,045*(14,723)97,684*(60,189)*(37,955)*49834,890*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Trevi Therapeutics54,302not reported(17,429)*142.5M18.3 quarters 10-QJun 30, 2026
Stoke Therapeutics107,27111,255(62,686)*65.4M5.2 quarters 10-QSep 30, 2026
Evolus41,70077,952(1,933)*66.2M7.7 quarters 10-QSep 30, 2026
Xencor59,622116,5202,642*75.0M— 10-QSep 30, 2026
Amphastar Pharmaceuticals223,614183,90351,324*42.5M— 10-QJun 30, 2026
Anaptysbio133,82627,488*(26,640)*29.9M6.2 quarters 10-KTJun 30, 2026
Savara41,800not reported(29,747)*205.5M5.8 quarters 10-QJun 30, 2026
Opko Health384,03665,414(36,315)*742.5M10.8 quarters 10-QSep 30, 2026
Iovance Biotherapeutics110,76899,313(60,841)*453.0M4.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.